Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas

被引：17

作者：

Heaney A.P. ^{[1
]}

Curry W.J. ^{[2
]}

Pogue K.M. ^{[2
]}

Armstrong V.L. ^{[1
]}

Mirakhur M. ^{[3
]}

Sheridan B. ^{[4
]}

Johnston C.F. ^{[2
]}

Buchanan K.D. ^{[2
]}

Atkinson A.B. ^{[1
]}

机构：

[1] Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast

[2] Department of Medicine, Centre for Endocrine Research, The Queen’s University of Belfast, Belfast

[3] Neuropathology Laboratory, Department of Pathology, Belfast

[4] Regional Endocrine Laboratory, Royal Victoria Hospital, Belfast

来源：

Pituitary | 2000年 / 3卷 / 2期

关键词：

Chromogranin A; Immunohistochemistry; Pituitary adenoma; Post-translational processing;

D O I：

10.1023/A:1009949623054

中图分类号：

学科分类号：

摘要：

Chromogranin A (CgA), pancreastatin (PST), intervening-peptide (IP) and WE-14 antisera were employed to investigate the proteolysis of CgA in 50 pituitary adenomas. All non-functioning (NF) pituitary tumours (n = 28) exhibited CgA immunoreactivity. PST, IP and WE-14 immunostaining was observed in 85%, 89% and 67%, respectively. CgA, PST and IP immunostaining were comparable in the majority of NF tumours, while less intense WE-14 immunoreactivity was detected in a subpopulation of NF tumour cells. Approximately half of the functioning pituitary tumours expressed CgA immunoreactivity. Six of nine ACTH-secreting tumours displayed CgA and IP immunostaining; four of these tumours displayed PST immunoreactivity. WE-14 immunoreactivity was detected in one corticotroph tumour. Three of six growth hormone (GH) secreting tumours displayed CgA immunostaining, two exhibited PST and IP, and one exhibited WE-14 immunoreactivity. Clusters of WE-14 immunopositive cells were detected in one GH tumour. One of seven prolactinomas exhibited weak CgA immunostaining, while weak IP and WE-14 immunostaining was detected in an additional tumour. No PST immunostaining was detected in prolactinomas. Therefore CgA is a valuable marker of NF pituitary tumours, however it is a more sporadic marker of functioning adenomas. In general, the cellular pattern and intensities of CgA, PST and IP immunoreactivity were comparable in the majority of pituitary adenomas. In contrast, WE-14 immunostaining was observed in a subpopulation of tumour cells. The pathophysiological significance of the proteolysis of CgA to generate bioactive peptides in both NF and functioning pituitary adenomas remains to be established.

引用

页码：67 / 75

页数：8

共 32 条

[1]

DeStephano D.B., Lloyd R.V., Pike A.M., Wilson B.S., Pituitary adenomas: An immunohistochemical study of hormone production and chromogranin localisation, Am J Pathol, 116, pp. 464-472, (1984)

[2]

Lloyd R.V., Cano M., Rosa P., Hille A., Huttner W.B., Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumours, Am J Pathol, 130, pp. 296-304, (1988)

[3]

Lloyd R.V., Wilson B.S., Kovacs K., Ryan N., Immunohistochemical localisation of chromogranin in human hypophyses and pituitary adenomas, Arch Pathol Lab Med, 109, pp. 515-517, (1985)

[4]

Deftos L.J., O'Connor D.T., Wilson C.B., Fitzgerald P.A., Human pituitary tumours secrete chromogranin-A, J Clin Endocrinol Metab, 68, pp. 869-872, (1989)

[5]

Schmid K.W., Kroll M., Hittmair A., Maier H., Totsch M., Gasser R., Finkenstett G., Hogue-Angeletti R., Fischer-Colbrie R., Chromogranin A and B in adenomas of the pituitary. An immunohistochemical study of 42 cases, Am J Surg Pathol, 15, pp. 1072-1077, (1991)

[6]

Jin L., Chandler W.F., Smart J.B., England B.G., Lloyd R.V., Differentiation of human pituitary adenomas determines the pattern of chromogranin/secretogranin messenger ribonucleic acid expression, J Clin Endocrinol Metab, 76, pp. 728-735, (1993)

[7]

Nobels F.R.E., Kwekkeboom D.J., Coopmans W., Hoekstra R., De Herder W.W., Bouillon R., Lamberts S.W.J., A comparison between the diagnostic value of gonadotrophins, alpha-subunit, and chromogranin-A and their response to thyrotrophin-releasing hormone in clinically nonfunctioning, adenomas, J Clin Endocrinol Metab, 77, pp. 784-789, (1993)

[8]

Wiedmann B., Huttner W.B., Synaptophysin and chromogranin/ secretogranins-widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumour diagnosis, Virch Arch B Cell Pathol, 58, pp. 95-121, (1989)

[9]

O'Connor D.T., Burton D., Deftos L.J., Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumours and normal endocrine tissues, J Clin Endocrinol Metab, 57, pp. 1084-1086, (1983)

[10]

Winkler H., Fischer-Colbrie R., The chromogranins A and B: The first 25 years and future perspectives, Neuroscience, 49, pp. 497-528, (1992)

← 1 2 3 4 →